HEART FAILURE POC AND LOC DEVICES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The global heart failure POC and LOC devices market is estimated to be valued at USD 185.7 Mn in 2026 and is expected to reach USD 498.4 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 15.1% from 2026 to 2033. Heart failure is a chronic, progressive disease of the cardiovascular system affecting more than 64 million people worldwide, where the heart fails to pump sufficient blood to meet the body’s oxygen and metabolic needs. The increasing disease burden is driving the need for rapid and accurate diagnostic solutions for biomarkers such as BNP, NT-proBNP, troponin.

Point-of-Care (POC) and Lab-on-Chip (LOC) devices are enabling rapid and decentralized cardiac testing in emergency departments, clinics, and home-care settings. Progress in microfluidics, biosensors, nanotechnology, and digital health is making these technologies more portable, accurate, and efficient, thus facilitating their expanding contribution to modern heart-failure diagnosis and monitoring.

Market Dynamics

The global heart failure POC and LOC devices market is driven by increase in the prevalence of heart failure as well as increase in the aging population along with increase in the prevalence of hypertension, diabetes, obesity and coronary artery disease. The increase in the preference for decentralized patient-centric care and advances in microfluidics, biosensors, wireless connectivity and artificial intelligence is further increasing the demand for rapid and accurate cardiac diagnostics in emergency, outpatient and remote-care settings.

However, a number of constraints are present in the market, such as high development and manufacturing costs, strict regulatory requirements, accuracy concerns, limited healthcare infrastructure, and reimbursement challenges. Nevertheless, growing demand for home-based cardiac monitoring, IoT-connected diagnostics, cloud-based data management, and predictive analytics, coupled with improving healthcare access in emerging economies will offer new opportunities for growth in the global heart failure POC and LOC devices market.

Key Features of the Study

• This report provides in-depth analysis of the global heart failure POC and LOC devices market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global heart failure POC and LOC devices market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Danaher Corporation, QuidelOrtho Corporation, bioMérieux S.A., Becton, Dickinson and Company, Trinity Biotech plc, Jant Pharmacal Corporation, and Werfen, S.A.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global heart failure POC and LOC devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global heart failure POC and LOC devices market

Market Segmentation

• Device Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Point-of-Care (POC) Devices
  • Lab-on-Chip (LOC) Devices
• Test Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Proteomic Testing
  • Metabolomic Testing
  • Genomic Testing
• Biomarker Insights (Revenue, USD Mn, 2021 - 2033)
  • BNP/NT-proBNP
  • Troponin
  • Multi-Biomarker Panels
  • Others
• Technology Insights (Revenue, USD Mn, 2021 - 2033)
  • Microfluidics
  • Array-Based Systems
  • Immunoassay-Based Systems
  • Others
• Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Acute Heart Failure Diagnosis
  • Chronic Heart Failure Monitoring
  • Risk Stratification and Readmission Prevention
  • Therapy Optimization
  • Others
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Specialty Cardiology Centers
  • Primary Care and Urgent Care Centers
  • Diagnostic Laboratories
  • Homecare and Remote Patient Monitoring
  • Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott Laboratories
  • Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Danaher Corporation
  • QuidelOrtho Corporation
  • bioMérieux S.A.
  • Becton, Dickinson and Company
  • Trinity Biotech plc
  • Jant Pharmacal Corporation
  • Werfen, S.A.